Atai Life Sciences N.V. is a biopharmaceutical company focused on developing innovative therapies for mental health conditions. The company leverages the potential of psychedelics and other novel compounds to address various psychiatric disorders, aiming to create safer and more effective treatment options. Through a unique platform, Atai collaborates with several research biotechnology companies, fostering an environment that promotes scientific discovery, clinical innovation, and the advancement of transformative therapies for individuals suffering from mental health challenges. Read More
Investors continue to monitor emerging growth companies across Artificial Intelligence (AI), Defense Technology, Biotechnology, Blockchain, Telecommunications, Digital Infrastructure, and Entertainment, as several small-cap stocks report significant operational and corporate developments.
BALA CYNWYD, Pa., July 16, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
Halper Sadeh LLC, an investor rights law firm, is investigating the sale of AtaiBeckley Inc. (NASDAQ: ATAI) to Eli Lilly and Company for $6.75 per share in cash, plus up to $2.50 per share in the form of a Contingent Value Right entitling the holder to additional cash payments upon achievement of specified development and regulatory milestones related to the BPL-003 and VLS-01 programs.
Gainers AtaiBeckley (NASDAQ:ATAI) stock rose 34.3% to $7.2 during Thursday's pre-market session. The market value of their outstanding shares is at $1.9 billion. Agape ATP (NASDAQ:ATPC) shares moved upwards by
NEW YORK, July 06, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced that the last patient has been dosed in Elumina, its Phase 2b clinical trial evaluating VLS-01 in adults living with treatment-resistant depression (TRD). The study randomized 156 patients, with topline data expected in Q4 2026.
NEW YORK, June 25, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced that it will be added to the Russell 2000® Index and the broad-market Russell 3000® Index, effective at the open of U.S. markets on June 29th as part of the first 2026 Russell indexes reconstitution.
NEW YORK, May 28, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced the launch of its Patient Impact Grant Program, which will award three grants of $20,000 each to non-profit, mission-driven organizations improving mental health outcomes through community leadership, education, and innovative research.
NEW YORK, May 27, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced that members of the Company’s management team will participate in multiple upcoming investor conferences in June 2026.
NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today reported financial results for the first quarter ended March 31, 2026, and provided a business update across its clinical pipeline.
NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced it has received the Silver Award in OVID Health’s 2026 Patient Participant Index (PPI), in collaboration with the Psychedelic Participant Advocacy Network (PsyPAN), in recognition of their joint efforts to strengthen participant partnership in psychedelic clinical research. The recognition highlights AtaiBeckley’s multiyear collaboration with PsyPAN to integrate the lived experiences of clinical trial participants into the responsible development of novel mental health therapies and amplify these learnings across the sector.
A renewed spotlight is forming around a group of small-cap healthcare companies as U.S. policy shifts toward accelerating research into psychedelic-based therapies for mental health disorders. Following a recent executive order aimed at expanding research pathways, companies below are drawing increased investor and industry attention as innovation and regulatory momentum converge.
